Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Cytarabine × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 52 Lymphoid 25 Myeloid 8 Plasma cell 4 Sarcoma 3 Classical hematology 2 Other neoplasm 1 Dermatologic 1 CNS 1

Conditions

Lymphoma 4 Neuroblastoma 2 Meningeal Carcinomatosis 2 Central Nervous System Neoplasms 2 Brain Neoplasms 2 Vasculitis, Central Nervous System 1 Thrombocytopenia 1 Stiff-Person Syndrome 1 Recurrence 1 Rasmussen subacute encephalitis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1 Opsoclonus-Myoclonus Syndrome 1 Neurotoxicity Syndromes 1 Neuromyelitis Optica 1 Neurofibromatosis 1 1 Myasthenia Gravis 1 Medulloblastoma 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myelomonocytic, Juvenile 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Lambert-Eaton Myasthenic Syndrome 1 Intraocular Lymphoma 1 HIV Infections 1 Ependymoma 1 Drug-Related Side Effects and Adverse Reactions 1 Breast Neoplasms 1 Autoimmune Diseases of the Nervous System 1 Autoimmune Diseases 1

Interventions

Temozolomide 21 Bevacizumab 18 Cyclophosphamide 7 Lomustine 6 Irinotecan 6 3-Iodobenzylguanidine 6 Topotecan 5 Radiotherapy 4 Radiosurgery 4 Nivolumab 4 Filgrastim 4 Everolimus 4 Carboplatin 4 fludarabine phosphate 3 Vincristine 3 Sirolimus 3 IL13-PE38 3 Etoposide 3 Drug Therapy 3 Busulfan 3 Antilymphocyte Serum 3 thymoglobulin 2 sonidegib 2 ribociclib 2 pembrolizumab 2 paclitaxel-Angiopep-2 conjugate 2 olaparib 2 fluorodopa F 18 2 fludarabine 2 avapritinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01356290 2026-02-23

MEMMAT

Medical University of Vienna

Phase 2 Recruiting

Ependymoma, Medulloblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡